Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Winston

Showing results (91-100 of 241) with videos related to

Pageof 25
Sort By:
The Journal of Antimicrobial Chemotherapy|February 20, 2015
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteersBorja Mora-Peris, Laura Else, David Goldmeier, et al.
Journal of the International AIDS Society|November 15, 2014
Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trialsJose Arribas, Pierre-Marie Girard, Nicholas Paton, et al.
International Journal of Tryptophan Research : IJTR|November 5, 2016
Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected IndividualsMichael R Keegan, Seetharamaiah Chittiprol, Scott L Letendre, et al.
Nutrients|September 19, 2018
The Decreasing Trend in Dietary Glycaemic Index and Glycaemic Load in Australian Children and Adolescents between 1995 and 2012Chris Ho Ching Yeung, Devina Tri Lestrai Kusnadi, Alan Winston Barclay, et al.
Journal of Neurovirology|August 20, 2025
Changes in cerebral function parameters in persons with HIV with symptoms of insomnia switching from dolutegravir- to bictegravir-based antiretroviral therapyMerle Henderson, Kate Alford, Samira Bouyagoub, et al.
HIV Clinical Trials|March 18, 2015
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of ageJaime H Vera, Akil Jackson, Laura Dickinson, et al.
AIDS (London, England)|April 20, 2004
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?Alan Winston, Anton Pozniak, Nicola Smith, et al.
Statistics in Medicine|November 29, 2016
Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatmentAlexina J Mason, Juan Gonzalez-Maffe, Killian Quinn, et al.
HIV Clinical Trials|April 16, 2015
Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controlsJane Ashby, Caroline Foster, Lucy Garvey, et al.
AIDS (London, England)|November 25, 2010
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirineLaura Waters, Martin Fisher, Alan Winston, et al.
Pageof 25

Showing results (91-100 of 241) with videos related to

Sort By:
Pageof 25
The Journal of Antimicrobial Chemotherapy|February 20, 2015
A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteersBorja Mora-Peris, Laura Else, David Goldmeier, et al.
Journal of the International AIDS Society|November 15, 2014
Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trialsJose Arribas, Pierre-Marie Girard, Nicholas Paton, et al.
International Journal of Tryptophan Research : IJTR|November 5, 2016
Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected IndividualsMichael R Keegan, Seetharamaiah Chittiprol, Scott L Letendre, et al.
Nutrients|September 19, 2018
The Decreasing Trend in Dietary Glycaemic Index and Glycaemic Load in Australian Children and Adolescents between 1995 and 2012Chris Ho Ching Yeung, Devina Tri Lestrai Kusnadi, Alan Winston Barclay, et al.
Journal of Neurovirology|August 20, 2025
Changes in cerebral function parameters in persons with HIV with symptoms of insomnia switching from dolutegravir- to bictegravir-based antiretroviral therapyMerle Henderson, Kate Alford, Samira Bouyagoub, et al.
HIV Clinical Trials|March 18, 2015
The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of ageJaime H Vera, Akil Jackson, Laura Dickinson, et al.
AIDS (London, England)|April 20, 2004
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?Alan Winston, Anton Pozniak, Nicola Smith, et al.
Statistics in Medicine|November 29, 2016
Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatmentAlexina J Mason, Juan Gonzalez-Maffe, Killian Quinn, et al.
HIV Clinical Trials|April 16, 2015
Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controlsJane Ashby, Caroline Foster, Lucy Garvey, et al.
AIDS (London, England)|November 25, 2010
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirineLaura Waters, Martin Fisher, Alan Winston, et al.
Pageof 25